Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Ubrogepant (Ubrelvy)

decorative image of the issue cover

Published October 1, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Ubrogepant (Ubrelvy), 50 mg and 100 mg oral tablets.
  • Indication: For the acute treatment of migraine, with or without aura, in adults.